Thompson Peter A. sold $5.3M of SION (indirect holdings)

Thompson Peter A. sold 115,844 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $45.50 ($5.27M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thompson Peter A.
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SION
Neutral
medium confidence
Mentioned
$SION
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIONNeutralLow
01

Why it matters

This is a director open-market sale under a Rule 10b5-1 plan, with no new company fundamentals provided in the filing excerpt.

02

Market read

Traders may monitor for continued insider selling, but the pre-arranged nature makes it unlikely to drive a major repricing by itself.

03

What to watch

Indirect holdings and the existence of a pre-arranged plan reduce interpretability; traders should look for additional Form 4 activity or other contemporaneous company catalysts.

Relevance 5/10Novelty 3/10Timing: filed July 2, 2026, covering a June 30 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Sionna Therapeutics, Inc. (SION).

Company-level read

Ticker impact

$SIONNeutralMedium confidence
Context

Sionna Therapeutics disclosed a director’s open-market sale of 115,844 shares at $45.50 on a 10b5-1 plan, totaling about $5.27M.

Expected impact

Limited near-term impact; any effect is likely short-lived unless follow-on selling accelerates or is paired with other new disclosures.

Evidence & confidence

Form 4 shows a planned sale by a director with no accompanying company-specific operational or financial update in the text.

Market effects

No clear sector read-through from a single planned director sale.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can be purely mechanical and may not reflect bearish expectations; it can even coincide with liquidity planning rather than information.

Key entities

  • Sionna Therapeutics, Inc.

    Company whose director’s Form 4 insider sale is disclosed.

  • Thompson Peter A.

    Director who sold 115,844 shares indirectly under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIONLowAI 8/10

Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary

Sionna Therapeutics reported a wider net loss of $32.42M in Q3 2026, up 59.9% YoY, due to increased R&D and administrative expenses. The company selected SION-451 + SION-2222 for its dual combination program but will not advance SION-719 after a failed trial. It reduced its workforce by 46% and expects its cash runway to extend into 2H 2029.

$SIONMed

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

$SIONMedAI 8/10

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

$SIONMed

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo